Perrigo Launch Investments Hold Income Back, As Firm Girds For 2013
This article was originally published in The Tan Sheet
Executive Summary
Perrigo’s consumer business’ 2012 full-year operating income, after GAAP adjustments, increased only 0.8% to $304.96 million, despite the division’s 8% revenue growth to $131 million for the fiscal year. The firm plans to launch more than 60 new products in fiscal 2013.
You may also be interested in...
Perrigo Campaigns For Rational OTC Shopping Over Brand Loyalty
The online “Store Brand Meds” campaign launched by Perrigo in early 2013 encourages consumers to “Make store brands your brand,” by emphasizing lower price points and equivalent active ingredients. Overcoming consumer connections to brands such as Tylenol is a challenge, however.
Perrigo Campaigns For Rational OTC Shopping Over Brand Loyalty
The online “Store Brand Meds” campaign launched by Perrigo in early 2013 encourages consumers to “Make store brands your brand,” by emphasizing lower price points and equivalent active ingredients. Overcoming consumer connections to brands such as Tylenol is a challenge, however.
Perrigo’s Mucinex Equivalent On The Cusp, But New Product Outlook Dims
The private labeler’s long-delayed guaifenesin launch now tentatively is set for March, CEO Joseph Papa says. But unclear timelines for other OTC launches caused Perrigo to lower its fiscal year consolidated new product sales outlook to $150 million from an initial projection of more than $190 million.